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Abstract 
MicroRNAs (miRNAs) are part of the epigenetic mechanisms that regulate gene expression at a post-transcriptional level. This review 
describes some miRNAs whose expression is modified in obesity and that may be involved in the development of insulin resistance. The 
metabolic alterations associated with obesity are due to an adipose tissue dysfunction. miRNAs are a mechanism that regulates gene 
expression, one miRNA can regulate the expression up to a thousand genes, and at the same time one gene can be regulated by several 
miRNAs; moreover, miRNA expression is tissue specific. Obesity leads to a dysregulation of miRNA expression in adipose tissue, and 
changes in miRNA expression relate to changes in gene expression related to the development of insulin resistance. However, because 
miRNA can be exported to the extracellular medium through exosomes, proteins, and lipoproteins, miRNA can be found in extracellular 
fluids like blood, urine, saliva, and cerebrospinal fluid. Considering the above, miRNA have been proposed as biological markers of dif-
ferent diseases, and also as potential therapeutic targets. (Endokrynol Pol 2021; 72 (1): 73–80)
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Introduction 
According to the World Health Organisation (WHO), 
overweight and obesity are defined as abnormal or 
excessive fat accumulation that may impair health [1]. 
In addition to the excess of fat accumulation, adipose 
tissue dysfunction is the cause of many metabolic al-
terations associated with obesity as insulin resistance 
(IR). Obesity leads to adipose tissue hypertrophy and 
hyperplasia. When the storage capacity of subcutane-
ous adipose tissue (SAT) adipocytes is exceeded, free 
fatty acids (FFA) accumulate in other organs, such as 
liver and skeletal muscle, favouring IR development 
[2]. Adipocyte hypertrophy promote the recruitment of 
circulating monocytes and activation of macrophages 
resident in adipose tissue, this favours proinflammatory 
cytokines such as tumour necrosis factor a (TNFa) and 
interleukin 6 (IL6) release, which in turn contribute 
to IR [3]. In addition, obesity causes dysregulation 
in the endocrine function of adipose tissue. Indeed, 
there is an increase in the expression and secretion of 
adipocytokines such as leptin, retinol binding protein 
4 (RBP4), and resistin, which promote IR; while there 
is also a reduction in the expression of adiponectin, 
which promotes insulin sensitivity [4–6]. Molecular 
mechanisms related to adipose tissue dysfunction are 
unknown in detail; however, epigenetic mechanisms 
such as miRNAs could explain changes in genetic ex-
pression in adipose tissue that are associated with IR 
development.
Obesity is the main factor related to IR
Insulin resistance is characterised by a dysfunction of 
insulin action, which provokes an increment of its con-
centrations in order to maintain normal blood glucose. 
Moreover, IR is an important predisposing factor to 
the type 2 diabetes mellitus (T2DM) development [2]. 
White adipose tissue (WAT) is composed of adipocytes 
and the fraction of the vascular stroma, which in turn 
is composed of preadipocytes, endothelial cells, fibro-
blasts, macrophages, leukocytes, and nerve fibres [7]. 
According to its distribution, WAT is divided into SAT 
and visceral adipose tissue (VAT). SAT is found under 
the skin in the abdominal, femoral, and gluteal areas, 
while VAT is located around vital organs, and inside 
the peritoneum and the thoracic cage [7]. One of the 
major functions of WAT is the storage of excess energy 
in the form of triglycerides during feeding, as well as its 
release as FFA and glycerol during fasting. Obesity leads 
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have been identified, of which 2654 correspond to 
mature miRNAs in humans [16]. miRNA genes can 
be located in intronic and intergenic genomic posi-
tions, but most of them are found in intergenic re-
gions. In humans, most of the miRNAs are transcribed 
as an independent transcriptional unit; however, 
some miRNAs are clustered in the genome and their 
transcription is regulated by the same promoter, so 
they are transcribed as a single polycistronic unit. 
miRNAs located in the intronic regions are released 
during splicing [12, 13]. 
miRNA biogenesis 
miRNAs are transcribed as primary transcripts 
(pri-miRNA) by RNA pol II. pri-miRNAs have a length 
of several kilobases and a hairpin structure. Like mes-
senger RNAs (mRNAs), miRNAs contain a 7-meth-
yl-guanosine cap at the 5 ‘end and a 3’-poly-(A). 
Inside the nucleus, pri-miRNAs are processed by 
a microprocessor, which consists of the RNase III-type 
endonuclease Drosha and the DGCR8 protein, which 
helps Drosha to recognise the pri-miRNA. This pro-
cess releases a 70-nucleotide stem-loop structure 
know as miRNA precursor (pre-miRNA) [12, 17]. The 
pre-miRNA is exported to the cytosol by an exporting 
5 protein and suffers a second processing by RNase III 
Dicer, initiating a double-strand mature miRNA with 
a length of around 22 nucleotides. Next, one of the 
mature miRNA strands is degraded while the other is 
loaded to an Argonaute protein, generating the miR-
NA-induced silencing complex (miRISC) [12, 13]. In hu-
mans, 4 subfamily members of the Argonaute protein 
have been identified (Ago 1-4), Ago2 being the only one 
with silencing activity [18]. The miRNA recognises, by 
base-pairing, a 3’ UTR region of mRNA. Unlike plants, 
in which the base-pairing between miRNA-mRNA is 
almost perfect, in animals this interaction is given in 
a specific region of the miRNA called the “seed”, cor-
responding to the 2–7 or 2–8 nucleotides in the 5’ end. 
Via miRISC, the interaction between miRNA-mRNA 
leads to the inhibition of the mRNA transcript transla-
tion and or its degradation [12] (Fig. 1). 
miRNA function 
The mechanisms by which miRNA mediate mRNA de-
cay and the repression of translation are not fully under-
stood. The miRNA-mRNA interaction attracts several 
protein complexes that induce mRNA deadenylation 
and decapping, this leads to mRNA being exposed to 
nuclease degradation. mRNA decay is the most com-
mon way in which miRNAs control gene expression in 
mammalians cells. Translation can be repressed at the 
to a hypertrophy and to a lesser extent to a hyperplasia 
of the adipocyte. When the storage capacity of the adi-
pocyte is exceeded, FFA accumulate in other organs and 
tissues leading to lipotoxicity. An increase in FFA causes 
beta cell dysfunction in the pancreas and favours IR 
development in the liver and skeletal muscles [8]. Oth-
erwise, adipocyte hypertrophy decreases blood flow to 
some adipocytes, which undergo hypoxia and death 
by necrosis. This triggers an inflammatory response, 
and circulating monocytes infiltrate adipose tissue and 
transform into macrophages, which form “crown-like 
structures” around dead adipocytes. Macrophages 
produce proinflammatory cytokines like TNFa and IL6, 
which in turn contribute to IR development [9]. Obesity 
is also characterised by an alteration in the endocrine 
function of adipose tissue; there is also an increase in 
the expression of adipocytokines like leptin, TNFa, IL6, 
resistin, visfatin, RBP4, and apelin, and a reduction of 
adiponectin expression; all these changes are related to 
IR development [10].
Currently, the molecular mechanisms explaining 
adipose tissue dysfunction associated with obesity are 
unknown. However, changes in gene expression could 
contribute to this pathological process, which leads to 
IR. Epigenetics is defined as heritable changes in gene 
expression without changes in the DNA sequence [11]. 
Epigenetic changes are reversible and are regulated 
by environmental factors such as diet, exercise, stress, 
alcohol consumption, smoking, and even factors such 
as the nutritional status of the mother. Among the epi-
genetic mechanisms are miRNA [11]. 
miRNAs are short single-stranded RNA 
molecules 
miRNAs are single-stranded RNA molecules, around 
22 nucleotides in length, of endogenous expression, 
which regulate gene expression at a posttranscriptional 
level [12]. For a small RNA to be considered a miRNA, it 
must meet the following criteria: it must have a length 
of 19–25 nucleotides; it must come from a precursor 
(around 60–80 nucleotides) capable of forming hairpin 
structures; and finally miRNAs are phylogenetically 
conserved [12].
miRNAs regulate the expression 
of a significant number of genes
miRNA-codifying genes represent 1% of the human 
genome, and it is thought that the expression of ap-
proximately 30% of all genes is regulated by miRNAs 
[13, 14]. A single miRNA can regulate the expression 
of up to a thousand genes, and one gene can be regu-
lated by several miRNAs [15]. To date, 38,589 miRNAs 
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initiation or during elongation, and in rare cases there 
may be a reduction of protein abundance without a de-
crease in the amount of the transcript [19, 20].
miRNAs are associated with obesity and IR
Obesity could lead to an altered expression of miR-
NAs, which is responsible for several metabolic altera-
tions. Several studies have found differences in miRNA 
expression in adipose tissue, between lean and obese 
subjects. Table 1 summarises the miRNA differentially 
expressed in adipose tissue from obese subjects.
Lethal-7 family (let-7)
The lethal-7 (let-7) was original identified in C. elegans, 
and it was the first known human miRNA. Studies have 
demonstrated a reduction of some let-7 family members 
in the SAT of obese subjects [21].
The let-7 family of miRNAs plays a key role in 
modulating inflammatory responses. Brennan et al. 
[22] found a reduction of ≈30% in let-7d expression in 
mouse vascular smooth muscle cells (SMC) treated with 
1 ng/mL of TNFa for 24 h. Likewise, let-7d reduced the 
proinflammatory cytokines IL6 and IL1b expression 
and NFkb activity in TNFa-treated SMC. These results 
were also confirmed in an ex-vivo transfection model 
in human carotid plaque tissue with let-7d resulting in 
a reduction of TNFa, IL1b, IFNg, and the vascular cell 
adhesion molecule 1 (ICAM1) expression [22]. Sung et 
al. [23] transfected bone marrow-derived mesenchymal 
stem cells with let-7c as a representative miRNA of the 
let-7 family. Transfection of this miRNA resulted in the 
repression of IL6 expression and a reduction in their 
protein levels. These authors found that IL6 is a target 
gene of for the let-7 microRNA.
Obesity and T2DM are associated with a reduction 
in plasmatic levels of several members of the let-7 family 
of miRNA, such as let7-a, let-7c, let-7d, let-7e, let-7f, and 
let-7g [24, 25]. Also, Arner et al. [21] found a reduction of 
let-7a and let-7d expression in the SAT of obese subjects 
compared to lean subjects. Thus, the reduction of the 
let-7 family of miRNA expression in obesity and T2DM 
could lead to an increase of proinflammatory cytokines 
that promote IR.
miR-193b
Obesity is associated to a reduction of miR-193b expres-
sion. Diverse studies have demonstrated a decrease in 
expression of this miRNA in adipose tissue from obese 
subjects, compared to lean subjects [21, 26]. Belarbi et 
al. [27] demonstrated that miR-193b overexpression 
induced greater adiponectin secretion in human SAT. 
Obesity is associated with a reduction of adiponectin 
plasmatic levels and also with a reduction in its expres-
sion in adipose tissue [28–30]. Adiponectin decreases 
IR in skeletal muscle by promoting FFA oxidation and 
also decreases the expression of gluconeogenic genes in 
liver [31, 32]. Apparently, miR-193b represses the expres-
Figure 1. miRNAs biogenesis. miRNAs are transcribed as primary transcripts (pri-miRNA) by RNA pol II. Inside the nucleus, pri-
miRNA is processed by the RNase III type endonuclease Drosha. This process releases a stem-loop structure know as miRNA precursor 
(pre-miRNA). The pre-miRNA is exported to the cytosol by an exportin 5 protein, and suffers a second processing by RNase III Dicer, 
giving rise to a double-strand mature miRNA with a length of around 22 nucleotides. Next, one of the mature miRNA strands is 
degraded while the other is loaded to Ago2, generating the miRNA-induced silencing complex (miRISC). Via miRISC, the interaction 
between miRNA-mRNA leads to the inhibition of the mRNA transcript translation and/or its degradation
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and to an increase in IL6 and CCL2 expression, leading 
to the development of IR. 
miR-221 family 
The miR-221 family is composed of two members: 
miR-221 and miR-222, and the expression of both 
miRNA is associated with obesity [21, 26, 38]. There 
is a direct relationship between BMI and miR-221 
expression in adipose tissue. Obese subjects have 
an increase in miR-221 expression in SAT, compared 
to normal weight subjects [38]. It has been reported 
that there is a decrease in miR-221 expression in SAT 
of obese subjects who suffer an important weight loss 
after surgery [39]. However, Prats-Puig et al. [40] found 
a miR-221 decrease in the plasma of obese children, 
compared to normal weight children. Also, Ortega et 
al. [41] showed that morbidly obese subjects have a de-
crease in the plasma miR-221. In the same study, these 
authors found that weight loss leads to an increase in 
plasmatic levels of miR-221 [40]. Conversely, Wang et 
al. [42] showed an increase in serum levels of miR-221 
in women with metabolic syndrome, compared to 
controls. Interestingly, miR-221 is overexpressed in 
adipose tissue from obese subjects, while apparently 
their circulating levels are lowered compared to nor-
sion of a subunit of the nuclear transcription factor g 
(NF-g), which decreases the activity of the adiponectin 
promoter activity nearly by 20% [27, 33]. 
It has also been demonstrated that miR-193b regu-
lates the expression of IL6. IL6 induces IR in liver and 
adipose tissue. This cytokine acts by a JAK/STAT3 sig-
nalling pathway that impairs insulin receptor substrate 
1 (IRS-1) phosphorylation and induces its degradation, 
leading to a disruption in insulin signalling [34, 35]. 
Interleukin 6 also promotes IR by inducing adipose 
tissue lipolysis [36]. miR-193b overexpression in hu-
man subcutaneous adipocytes attenuates IL6 secre-
tion [21]. Another gene regulated by miR-193b is the 
chemokine (C-C motif) ligand 2 (CCL2), also referred 
to as monocyte chemoattractant protein 1 (MCP-1). 
CCL2 is a chemokine produced in adipose tissue 
that triggers the infiltration of circulating monocytes, 
activating the inflammatory response responsible for 
IR [37]. miR-193b decreases CCL2 secretion from hu-
man subcutaneous adipocytes. Although CCL2 is not 
a direct target of miR-193b, it has been shown that this 
miRNA regulates the expression of this chemokine 
by regulating the expression of transcription factors, 
which in turn regulate its expression [27]. Thus, the 
reduction of miR-193b expression associated with 
obesity leads to a decrease in adiponectin expression 
Table 1. miRNA dysregulated in white adipose tissue (WAT) of obese humans
Author WAT depot Groups of study Upregulated miRNA Downregulated miRNA
Martinelli et al. 
(2010) [58] SAT
Control  (BMI < 30, n = 9)
Obese  (BMI > 40, n = 10)
miR-519d, miR-498, miR-150 miR-659, miR-371-3p
Ortega et al. 
(2010) [38] SAT
Control (BMI < 30, n = 6)
Obese without T2DM (BMI > 40, n = 13)
Obese with T2DM (BMI > 40, n = 7)
Obese without T2DM vs. control
miR-185, miR-139-5p,  
miR-484, miR-130b
miR-221, miR-125b, miR-99a 
miR-1229
Obese without T2DM vs. obese with T2DM
miR-484, miR-130b, 
miR-K12-7
miR-221, miR-125b,  
miR-199a-5p, miR-1229
Heneghan et al. 
(2011) [60] VAT
Control (BMI < 25, n = 10)
Obese (BMI >40, n = 19)
– miR-17-5p, miR-132
Arner et al. 
(2012) [21] SAT
Control (BMI < 30, n = 20)
Obese (BMI > 30, n = 30)
–
miR-26a, miR-92a, miR-30c, 
miR-126, miR-143, miR-145, 
miR-193a-5p, miR-652,  
miR-let7a, miR-let 7d
Meerson et al. 
2013 [26] SAT
Control (BMI < 30, n = 9)
Obese (BMI > 37, n = 10)
miR-221, miR-146a, miR-494, 
miR-146b
miR-139, miR-193a,  
miR-193b-5p, miR-500
Liu et al.  
2016 [57] VAT
Control (BMI < 30, n = 6)
Obese (BMI > 30, n = 6)
miR-1934
Deiuliis et al. 
2016 [51] VAT
Control (BMI < 25, n = 21)
Obese (BMI > 25, n = 14)
miR-223
BMI — body mass index [kg/m2]; T2DM — type 2 diabetes mellitus; SAT — subcutaneous adipose tissue; VAT — visceral adipose tissue; WAT — white adipose 
tissue
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mal-weight subjects. Although it is clear that obesity 
is associated to a dysregulation of miR-221 expression, 
future research needs to be focused in explaining the 
differences between what is found in adipose tissue 
and circulating levels. This could clarify the poten-
tial role of miR-221 as a clinical marker of metabolic 
disease.  Moreover, miR-221 is associated with IR via 
controlling the expression of the adiponectin recep-
tor-1 (ADIPOR1). There are two adiponectin recep-
tors: ADIPOR1 and ADIPOR2. ADIPOR1 is expressed 
ubiquitously, whereas ADIPOR2 is expressed mainly 
in liver [43]. miRNA-221 is directly downregulated 
by ADIPOR1, but not by ADIPOR2. According to 
Meerson et al. [26], transfection to HEK293 cells and 
human preadipocytes with miR-221 mimics resulted 
in a reduction of ADIPOR1 protein levels without al-
terations in its mRNA. These results are in agreement 
with those reported by Lustig et al. [44], in which 
overexpression of miR-221 in HepG2 cells decreased 
ADIPOR1 protein levels, without ADIPOR1 mRNA 
changes.  Sirtuin 1 (SIRT1) is another direct target of 
miR-221 [45]. SIRT1 belongs to the histone deacetylases 
that depend on the NAD+ family. The expression of 
this protein promotes an increase of insulin sensitivity 
in adipose tissue, increasing adiponectin expression 
and decreasing the expression of some proinflamma-
tory cytokines such as IL6, TNFa, CCL2, JNK, and IL1b 
[46, 47]. Low chronic inflammation is a characteristic 
of obesity, and it is closely related to IR. On the other 
hand, it has been demonstrated that inflammation 
plays an important role in the regulation of miR-221 
expression. Using the media of pro-inflammatory 
M1-like phenotype macrophage with liposaccharide 
(LPS), Ortega et al. [39] demonstrated that inflamma-
tion induces an increase in miR-221 expression in hu-
man mature adipocytes. Peng et al.  [45] showed that 
treatment with 10 ng/mL of TNFa for 24 h in 3T3-L1 
adipocytes resulted in miR-221 overexpression. These 
results differ from those reported by Meerson et al. 
[26], in which the authors showed that in preadipo-
cytes 3T3-L1 treatment with leptin (at concentrations 
of 50, 200, and 500 ng/mL) or TNFa (at 5 and 500 ng/mL) 
for 24 h downregulates the miR-221 expression. Further 
studies are needed to elucidate the effect of inflamma-
tion in the regulation of miR-221 expression, whose 
effect probably differs from the preadipocyte to the 
mature adipocyte. 
miR-222 is implicated in the regulation of insulin 
sensitivity. Transfection of miR-222 in 3T3-L1 cells de-
crease GLUT4 expression, while the silencing of this 
miRNA reduces insulin-stimulated glucose uptake 
by ≈40% [48]. GLUT4 expression is an indicator of 
the adipocyte response to insulin action. Obesity and 
T2DM are associated with SAT GLUT4 expression 
reduction [49].
miR-223 
miR-223 is associated with regulation of  glucose homeo-
stasis and inflammatory response [50, 51]. Chuang et al. 
[50] demonstrated that miR-223 is overexpressed in SAT 
from women with IR. The overexpression of this miRNA 
in human adipocytes inhibits glucose uptake stimulated 
by insulin, and it also decreases protein abundance of 
GLUT4 without an effect on the transcript abundance. 
Deiuliis et al. [51] found that miR-223-3p is upregulated 
in human VAT from obese subjects. According to these 
authors, the upregulation of this miRNA expression 
is specific to the stromal vascular cells of human VAT. 
miR-223 plays a role in macrophage infiltration to adi-
pose tissue, by controlling the expression of the Toll-like 
receptor 4 (TLR4) [51]. Obesity leads to an increase of 
FFA from the diet or adipose tissue lipolysis. The TLR4 
is activated by FFA, which promotes downstream 
NF-kb signalling, leading to the expression of several 
chemokines, such as CCL2 [37].  
miR-130 
The miR-130 family consists of four members; miR-130a, 
miR-130b, miR-301a, and miR-301b. Studies show that 
the expression of miR-130a and miR-130b is repressed in 
the SAT of obese subjects, and that they have as a direct 
target the peroxisome proliferator-activated receptor g 
(PPARg) [38, 52].
PPARg is a transcription factor known as the master 
regulator of adipogenesis. The activation of PPARg 
represses the expression of proinflammatory genes 
TNFa, IL6, and IL1b, and it up-regulates adiponectin 
expression [53]. In obese subjects there is an increase 
in PPARg expression in SAT; however, the expression 
of this transcription factor is reduced in obese subjects 
with metabolic alterations [54, 55]. Changes in PPARg 
expression can act as an adaptive mechanism at the 
onset of obesity, and its expression can be affected by 
other metabolic alterations [55].
Other miRNA families
The miR-378 family consists of five members, and over-
expression of one family member has been reported 
in SAT in obese individuals. The adiponectin gene is 
a direct target of miR-378 [38, 56]. 
miR-1934 is repressed in VAT of obese individuals, 
and this miRNA inhibits IL6, IL1b, and CCL2 expres-
sion [57]. Resistin is another target of miR-1934; serum 
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resistin levels are increased in obese subjects and its 
concentrations are directly associated with IR [4, 57].
The miR-515 family has 51 members, and miR-519 
belongs to this family. miR-519 has been found to be 
overexpressed in the SAT of individuals with morbid 
obesity. Transcription factor PPARa is a direct target of 
miR-519d [58]. PPARa regulates the expression of dif-
ferent genes involved in b-oxidation, such as carnitine 
palmitoyl transferase and acyl-CoA oxidase; its activa-
tion promotes FFA oxidation, which reduces IR [59]. 
miR-126 is repressed in SAT in obese individuals, and 
CCL2 is a direct target of this miRNA [15, 25, 27]. 
Conclusions 
Obesity leads to an adipose tissue dysfunction that 
is responsible for metabolic alterations such as IR. 
Epigenetics could explain some of the molecular 
mechanisms responsible for adipose tissue dysfunc-
tion. miRNAs are small, single-stranded RNAs of en-
dogenous expression, which regulate gene expression 
at a post-transcriptional level. miRNAs normally bind 
to a target mRNA, and the miRNA-mRNA interaction 
results in mRNA translation inhibition or degradation. 
Obesity is associated with changes in miRNA expres-
sion in adipose tissue, this leads to overexpression or 
repression of genes implicated in IR development. 
Figure 2 summarises the changes in miRNA expression 
in adipose tissue of obese subjects and their relationship 
with IR development. miRNAs have been proposed as 
possible biological markers and therapeutic targets in 
some diseases, such as obesity. 
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